Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win

Novo Nordisk has launched an oral version of its blockbuster weight loss drug Wegovy, marking a significant shift in the GLP-1 market. However, analysts argue that rival Eli Lilly (NYSE: LLY) may still be the bigger winner, thanks to its drug Zepbound and superior manufacturing capacity.

The Product

The oral Wegovy pill is the first oral GLP-1 drug for weight loss, eliminating the need for injections. It contains the same active ingredient, semaglutide, as the injectable Wegovy and Ozempic. The pill aims to improve patient convenience and adherence.

Pricing and Availability

Novo Nordisk has not yet announced official pricing, but it is expected to be lower than the injectable version to broaden access. The pill will be available by prescription only.

Competition

Eli Lilly's Zepbound (tirzepatide) has shown superior weight loss results compared to semaglutide. Lilly also has greater manufacturing capacity, giving it a competitive edge. Additionally, Lilly is developing its own oral GLP-1 drug.

Potential Impact on Eli Lilly

The launch of the oral pill could expand the overall GLP-1 market, benefiting all players. However, Eli Lilly, with its more effective drug and manufacturing strength, may be better positioned to capture a larger share. The key question is whether Novo Nordisk can close the gap.